PURPOSE OF REVIEW: The management of hypertrophic cardiomyopathy (HCM) has changed considerably over the years, although molecular therapies targeting core mechanisms of the disease are still lacking. This review provides an overview of the contemporary medical approach to patients with HCM, and of promising novel developments hopefully soon to enter the clinical arena. RECENT FINDINGS: Our perception of therapeutic targets for medical therapy in HCM is rapidly evolving. Novel approaches include myocardial metabolic modulation, late sodium current inhibition, and allosteric myosin inhibition, actively pursued to reduce and hopefully prevent the development of severe HCM phenotypes, improve symptom control, and preserve patients from disease-related complications. Clinical management of patients with HCM should be guided by in-depth knowledge of the complex mechanisms at the energetic, metabolic, and electrophysiologic level. Until new experimental therapies become available, tailored management of modifiable disease manifestations should be pursued, including lifestyle counseling and prevention of comorbidities.
PURPOSE OF REVIEW: The management of hypertrophic cardiomyopathy (HCM) has changed considerably over the years, although molecular therapies targeting core mechanisms of the disease are still lacking. This review provides an overview of the contemporary medical approach to patients with HCM, and of promising novel developments hopefully soon to enter the clinical arena. RECENT FINDINGS: Our perception of therapeutic targets for medical therapy in HCM is rapidly evolving. Novel approaches include myocardial metabolic modulation, late sodium current inhibition, and allosteric myosin inhibition, actively pursued to reduce and hopefully prevent the development of severe HCM phenotypes, improve symptom control, and preserve patients from disease-related complications. Clinical management of patients with HCM should be guided by in-depth knowledge of the complex mechanisms at the energetic, metabolic, and electrophysiologic level. Until new experimental therapies become available, tailored management of modifiable disease manifestations should be pursued, including lifestyle counseling and prevention of comorbidities.
Authors: Tomoko S Kato; Hiroo Takayama; Saeko Yoshizawa; Charles Marboe; P Christian Schulze; Maryjane Farr; Yoshifumi Naka; Donna Mancini; Mathew S Maurer Journal: Am J Cardiol Date: 2012-05-15 Impact factor: 2.778
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff Journal: Circulation Date: 2013-06-05 Impact factor: 29.690
Authors: Mark V Sherrid; Ivan Barac; William J McKenna; Perry M Elliott; Shaughan Dickie; Lidia Chojnowska; Susan Casey; Barry J Maron Journal: J Am Coll Cardiol Date: 2005-04-19 Impact factor: 24.094
Authors: Zahara Meghji; Anita Nguyen; Benish Fatima; Jeffrey B Geske; Rick A Nishimura; Steve R Ommen; Brian D Lahr; Joseph A Dearani; Hartzell V Schaff Journal: JAMA Cardiol Date: 2019-03-01 Impact factor: 14.676
Authors: Caroline J Coats; Menelaos Pavlou; Oliver T Watkinson; Alexandros Protonotarios; Linda Moss; Rebecca Hyland; Khadija Rantell; Antonis A Pantazis; Maite Tome; William J McKenna; Michael P Frenneaux; Rumana Omar; Perry M Elliott Journal: JAMA Cardiol Date: 2019-03-01 Impact factor: 14.676
Authors: Josef Veselka; Morten Kvistholm Jensen; Max Liebregts; Jaroslav Januska; Jan Krejci; Thomas Bartel; Maciej Dabrowski; Peter Riis Hansen; Vibeke Marie Almaas; Hubert Seggewiss; Dieter Horstkotte; Pavol Tomasov; Radka Adlova; Henning Bundgaard; Robbert Steggerda; Jurriën Ten Berg; Lothar Faber Journal: Eur Heart J Date: 2016-01-07 Impact factor: 29.983